Welcome to our dedicated page for Dyadic Intl Del SEC filings (Ticker: DYAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyadic International, Inc. filings document the regulatory disclosures of a Nasdaq-listed biotechnology company developing and commercializing recombinant proteins and enzymes through proprietary microbial expression platforms. Form 8-K reports cover financial results, press-release exhibits, business-development updates, and Nasdaq continued-listing matters affecting the company's common stock.
The filing record also includes material agreements and capital-structure disclosures, including equity issuance programs under shelf registration statements, underwriting arrangements for common stock offerings, and amendments to security agreements tied to senior secured convertible promissory notes. These documents describe Dyadic's governance, registered securities, financing activity, listing compliance, and formal event reporting.
Dyadic International, Inc. (Nasdaq: DYAI) received a Nasdaq Listing Qualifications notice on 17-Jul-2025 after its common stock failed to meet the $1.00 minimum bid price for the past 30 consecutive business days, violating Rule 5550(a)(2).
The notice does not immediately affect DYAI’s listing. The company has 180 calendar days—until 13-Jan-2026—to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive trading days. If the requirement is unmet, Dyadic may qualify for a second 180-day grace period, provided it satisfies all initial listing standards other than bid price and formally notifies Nasdaq of its remediation plan. Failure to cure could result in delisting, with the option to appeal.
Management “intends to actively monitor” share price and explore alternatives to resolve the deficiency. The filing also reminds investors that the company remains out of compliance with the $35 million Market Value of Listed Securities rule (Rule 5550(b)(2)); that separate deficiency must be remedied by 20-Dec-2025. Either unresolved deficiency can independently trigger delisting.
Dyadic International (NASDAQ:DYAI) filed an 8-K disclosing receipt of a Nasdaq Listing Rule 5550(b)(2) deficiency notice for failing to maintain the minimum $35 million Market Value of Listed Securities (MVLS).
The stock has been below the threshold for 30 consecutive business days, activating a 180-day cure period ending December 20, 2025. To regain compliance, DYAI’s MVLS must close at or above $35 million for at least 10 consecutive trading days before the deadline. Failure would prompt a delisting determination, which the company could appeal, though success is not assured.
The notice has no immediate effect on Nasdaq trading but flags heightened liquidity and financing risk. Management says it will monitor MVLS and “evaluate available options,” yet outlines no specific actions. Forward-looking statements reiterate ongoing losses, capital needs, and potential breaches of other listing standards, underscoring uncertainty for shareholders.
Dyadic International, Inc. (NASDAQ: DYAI) filed an 8-K to disclose the final results of its 20 June 2025 Annual Meeting of Shareholders.
- Director election – Class III: Founder & CEO Mark A. Emalfarb was re-elected to serve until the 2028 meeting with 15,946,385 votes FOR (96.0% of votes cast) versus 421,896 WITHHELD and 7,892,709 broker non-votes.
- Auditor ratification: Crowe LLP was confirmed as independent registered public accounting firm for FY-2025 with an overwhelming 24,013,307 FOR (99.0%), 237,523 AGAINST and 10,160 ABSTAIN.
- Say-on-pay (advisory): Compensation of named executive officers received 15,765,072 FOR (95.9%), 522,744 AGAINST, 80,465 ABSTAIN, and 7,892,709 broker non-votes.
- Say-on-pay frequency: Shareholders strongly preferred an annual advisory vote: 15,443,558 votes for 1-year, handily exceeding 716,692 (2-years) and 13,576 (3-years). Abstentions were 194,455.
Based on these results, the Board and its Compensation Committee have resolved that future advisory votes on executive compensation will be held once every year.
No other matters were brought before the meeting, and there were no disclosures of earnings, major transactions or material events beyond the voting outcomes.
Dyadic International, Inc. (DYAI) – Form 4 insider filing details the June 20, 2025 vesting and conversion of 10,776 restricted stock units (RSUs) held by outgoing director Michael P. Tarnok.
The RSUs automatically vested "upon retirement from service as a member of the board of directors," and were converted into an equal number of DYAI common shares. Transaction code M denotes an exempt, non-open-market conversion; no shares were sold and no cash price was paid (exercise price reported as $0).
Following the transaction Mr. Tarnok’s direct beneficial ownership rises to 281,033 common shares, reinforcing post-retirement equity alignment. The filing, signed June 24, 2025, indicates the action was performed by an attorney-in-fact on the insider’s behalf. No 10b5-1 trading plan box is checked, and there are no derivative instruments remaining.
For investors, the disclosure is largely administrative. The conversion results in a modest 0.04 % increase to Dyadic’s basic share count (based on ~26 M shares outstanding as of the last 10-K) and signals a board transition already in progress. No information on replacement directors, strategic impact, or cash compensation is provided in this filing.
Dyadic International, Inc. (DYAI) – Form 4 insider filing
Director Arindam Bose reported changes in his beneficial ownership effective 20 June 2025.
- Non-derivative transaction (Table I): Code M indicates the exercise/settlement of Restricted Stock Units (RSUs), resulting in the acquisition of 10,776 common shares. Post-transaction, Bose directly owns 61,535 DYAI shares.
- Derivative transactions (Table II): • One RSU grant (10,776 units) was settled into common stock (Code M). • A separate RSU grant of identical size was forfeited upon Bose’s retirement from the Board (Code D). No derivative securities remain outstanding for the reporting person.
- Reason for changes: Vested RSUs were converted to stock, while unvested RSUs were forfeited in connection with the director’s retirement.
The filing does not disclose any purchase price (exercise price shown as $0), suggesting these were cost-free equity settlements typical of service-based RSUs. The net effect is a shift of Bose’s exposure from derivative to direct equity ownership without cash inflow/outflow for DYAI. No additional corporate events, earnings data or large-scale insider sales are reported in this filing.